Fabrication and Evaluation of Spironolactone-Loaded Nanostructured Lipid Carries for Cardiac Tissue Regeneration

Mehrzad Falak, Mehdi Mehdikhani, Jaleh Varshosaz, Batool Hashemibeni, Mehdi Ebrahimian-Hosseinabadi

DOI: 10.4103/jmss.JMSS_46_19


Background: Spironolactone (SP) is a lipophilic aldosterone receptor antagonist that few studies have reported its effect on cardiac remodeling. In addition, fewer researches have considered its influence on cardiomyocyte viability and potential benefits for myocardial tissue remodeling. Methods: In this study, stearic acid (SA) (solid lipid) and oleic acid (OA) (liquid lipid) were utilized to produce nanostructured lipid carries (NLCs) (various ratios of SA to OA and water amount, F1: 80:20 [30 ml water], F2: 80:20 [60 ml water], F3: 70:30 [30 ml water], and F4: 70:30 [60 ml water]) containing SP and their particle size, polydispersity index, zeta potential, entrapment efficiency, and release profile were measured. The purpose of encapsulating SP in NLCs was to provide a sustain release system. Meanwhile, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay with different concentrations of SP-loaded NLCs (SP-NLCs) was conducted to evaluate the cytotoxicity of the NLCs on rat myocardium cells (H9C2). Results: Increase of oil content to 10 wt% reduced the particle size from 486 nm (F1) to 205 nm (F2). Zeta potential of the samples at around -10 mV indicated their agglomeration tendency. After 48 h, SP-NLCs with the concentrations of 5 and 25 icro M showed significant improvement in cell viability while the same amount of free SP-induced cytotoxic effect on the cells. SP-NLCs with higher concentration (50 Micro M) depicted cytotoxic effect on H9C2 cells. Conclusions: It can be concluded that 25 Micro M SP-NLCs with sustain release profile had a beneficial effect on cardiomyocytes and can be used as a mean to improve cardiac tissue regeneration.


Cardiac tissue regeneration, nanostructures lipid carriers, spironolactone, sustain release

Full Text:



McAloon CJ, Boylan LM, Hamborg T, Stallard N, Osman F, Lim PB, et al. The changing face of cardiovascular disease 2000-2012: An analysis of the world health organisation global health estimates data. Int J Cardiol 2016;224:256-64.

Senel Ayaz HG, Perets A, Ayaz H, Gilroy KD, Govindaraj M, Brookstein D, et al. Textile-templated electrospun anisotropic scaffolds for regenerative cardiac tissue engineering. Biomaterials 2014;35:8540-52.

Hermidorff MM, Faria Gde O, Amancio Gde C, de Assis LV, Isoldi MC. Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: Do they evoke cardioprotective pathways? Biochem Cell Biol 2015;93:83-93.

Wu CT, Wang ZH, Li ZQ, Wang LF. Effect of spironolactone on cardiac remodeling after acute myocardial infarction. World J Emerg Med 2013;4:48-53.

Shamma RN, Aburahma MH. Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. Int J Nanomedicine 2014;9:5449-60.

Kelidari HR, Saeedi M, Akbari J, Morteza-Semnani K, Valizadeh H, Maniruzzaman M, et al. Development and optimisation of spironolactone nanoparticles for enhanced dissolution rates and stability. AAPS PharmSciTech 2017;18:1469-74.

Kelidari HR, Saeedi M, Hajheydari Z, Akbari J, Morteza-Semnani K, Akhtari J, et al. Spironolactone loaded nanostructured lipid carrier gel for effective treatment of mild and moderate acne vulgaris: A randomized, double-blind, prospective trial. Colloids Surf B Biointerfaces 2016;146:47-53.

Khalil RM, Abd-Elbary A, Kassem MA, Ghorab MM, Basha M. Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam. Pharm Dev Technol 2014;19:304-14.

Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: Retrospective study. BMJ 2003;327:1141-2.

Stubnova V, Os I, Grundtvig M, Atar D, Waldum-Grevbo B. Spironolactone treatment and effect on survival in chronic heart failure patients with reduced renal function: A propensity-matched study. Cardiorenal Med 2017;7:128-36.

Marrs JC, Anderson SL, Gabriel CH. Role of aldosterone receptor antagonists in heart failure with preserved ejection fraction. Clin Med Insights Ther 2018;10:1-9.

Lund LH, Svennblad B, Melhus H, Hallberg P, Dahlstrom U, Edner M. Association of spironolactone use with all-cause mortality in heart failure: A propensity scored cohort study. Circ Heart Fail 2013;6:174-83.

Ferreira JP, Rossignol P, Pizard A, Machu JL, Collier T, Girerd N, et al. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. Heart 2019;105:307-14.

Minicucci MF, dos Santos PP, Rafacho BP, Gonçalves AF, Silva RA, Chiuso-Minicucci F, et al. Mechanisms involved in the beneficial effects of spironolactone after myocardial infarction. PLoS One 2013;8:E76866.

Hendradi E, Rosita N, Rahmadhanniar E. Effect of lipid ratio of stearic acid and oleic acid on characteristics of nanostructure lipid carrier (NLC) system of diethylannonium diclofenac. Indonesian J Pharm 2017;4:198-204.

Beloqui A, Solinis MA, Delgado A, Evora C, Isla A, Rodriguez-Gascon A. Fate of nanostructured lipid carriers (NLCs) following the oral route: Design, pharmacokinetics and biodistribution. J Microencapsul 2014;31:1-8.

Kelidari HR, Saeedi M, Akbari J, Morteza-Semnani K, Gill P, Valizadeh H, et al. Formulation optimization and in vitro skin penetration of spironolactone loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces 2015;128:473-9.

Peppas NA, Brannon-Peppas L. Water diffusion and sorption in amorphous macromolecular systems and foods. In: Water in Foods. 1st ed. Journal of Food engineering: Elsevier; 1994. p. 189-210. DOI: 10.1016/0260-8774(94)90030-2.

Gou M, Li X, Dai M, Gong C, Wang X, Xie Y, et al. A novel injectable local hydrophobic drug delivery system: Biodegradable nanoparticles in thermo-sensitive hydrogel. Int J Pharm 2008;359:228-33.

Jensen A, Lim LT, Barbut S, Marcone M. Development and characterization of soy protein films incorporated with cellulose fibers using a hot surface casting technique. LWT-Food Sci Technol 2015;60:162-70.

Knights KM, Bowalgaha K, Miners JO. Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18B-glucuronidation. Potential Drug Interactionv 2010;38:1011-4.

Gokce EH, Korkmaz E, Dellera E, Sandri G, Bonferoni MC, Ozer O. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: Evaluation of antioxidant potential for dermal applications. Int J Nanomedicine 2012;7:1841-50.

Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection. Eur J Pharm Sci 2009;38:138-46.

Elmowafy M, Ibrahim HM, Ahmed MA, Shalaby K, Salama A, Hefesha H. Atorvastatin-loaded nanostructured lipid carriers (NLCs): Strategy to overcome oral delivery drawbacks. Drug Deliv 2017;24:932-41.

Azhar Shekoufeh Bahari L, Hamishehkar H. The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; A comparative literature review. Adv Pharm Bull 2016;6:143-51.

Akhoond Zardini A, Mohebbi M, Farhoosh R, Bolurian S. Production and characterization of nanostructured lipid carriers and solid lipid nanoparticles containing lycopene for food fortification. J Food Sci Technol 2018;55:287-98.

Suttiponparnit K, Jiang J, Sahu M, Suvachittanont S, Charinpanitkul T, Biswas P. Role of surface area, primary particle size, and crystal phase on titanium dioxide nanoparticle dispersion properties. Nanoscale Res Lett 2011;6:27.

Yu Q, Hu X, Ma Y, Xie Y, Lu Y, Qi J, et al. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus. Drug Deliv 2016;23:1469-75.

Shalaby KS, Soliman ME, Casettari L, Bonacucina G, Cespi M, Palmieri GF, et al. Determination of factors controlling the particle size and entrapment efficiency of noscapine in PEG/PLA nanoparticles using artificial neural networks. Int J Nanomedicine 2014;9:4953-64.

Benson HA, Sarveiya V, Risk S, Roberts MS. Influence of anatomical site and topical formulation on skin penetration of sunscreens. Therapeutics Clin Risk Manag 2005;1:209.

Gaba B, Fazil M, Ali A, Baboota S, Sahni JK, Ali J. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv 2015;22:691-700.


  • There are currently no refbacks.